Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
We recommend
Current Reimbursement Conditions for the Dual Inhibitor IL-4/IL-13 Dupilumab
The biologic dupilumab is approved for the treatment of several diseases with type 2 inflammation. What is the current reimbursement situation in key indications? We summarize in the following brief overview.
Doc. Miloslav Salavec: We Still Encounter Delayed Initiation of Biological Treatment in AD and Many Other Diagnoses
Not all patients with atopic dermatitis (AD) who are indicated for biological treatment with…
Laboratory Safety of Dupilumab Treatment in Children with Atopic Dermatitis Aged 6 Months to 6 Years
Previous clinical studies in children aged 6–12 years with moderate-to-severe atopic dermatitis…
Articles on this topic
Journal articles Asthma bronchiale in the context of internal medicine
Úvodem poněkud kacířské tvrzení: astma je dnes „dobrá diagnóza“.
Na rozdíl od ostatních nemocí...
Journal articles Skin conditions in patients with inflammatory bowel diseases
Idiopatické střevní záněty (IBD – inflammatory bowel diseases) se mohou manifestovat také na...
1
2
Subscribe
E-courses on this topic
Most read on this topic
- Skin conditions in patients with inflammatory bowel diseases
- Asthma bronchiale in the context of internal medicine
- Dupilumab Now Covered for Atopic Dermatitis in Children Older Than 6 Years
- What is new in the treatment of atopic dermatitis and how are comorbidities affecting it?
- Comparison of Biologics in the Treatment of Chronic Rhinosinusitis with Nasal Polyps
- Infographic and Commentary from Practice: Reasons and Pathways for Patients to Biological Treatment of Asthma
Journal on this topic
Related topic